Patents by Inventor Thomas Allen Chappie

Thomas Allen Chappie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazopyridazine compounds
    Patent number: 10077269
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: September 18, 2018
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young, Patrick Robert Verhoest
  • Azabenzimidazole compounds
    Patent number: 9815832
    Abstract: The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 14, 2017
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward
  • Pyrazolopyrimidine Compounds
    Publication number: 20170204099
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R3, and b are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Application
    Filed: July 10, 2015
    Publication date: July 20, 2017
    Applicant: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Travis T. Wager, Erik Alphie LaChapelle, Joseph Michael Young
  • Imidazopyridazine Compounds
    Publication number: 20170145022
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Application
    Filed: February 7, 2017
    Publication date: May 25, 2017
    Applicant: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young, Patrick Robert Verhoest
  • Imidazopyridazine compounds
    Patent number: 9598421
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 21, 2017
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young
  • Triazine derivatives
    Patent number: 9296761
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: March 29, 2016
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Imidazopyridazine Compounds
    Publication number: 20160039828
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Application
    Filed: August 4, 2015
    Publication date: February 11, 2016
    Applicant: PFIZER INC.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young
  • Triazine Derivatives
    Publication number: 20150353579
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Application
    Filed: August 19, 2015
    Publication date: December 10, 2015
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
    Patent number: 9200000
    Abstract: The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: December 1, 2015
    Assignee: Pfizer Inc.
    Inventors: Christopher John Helal, Thomas Allen Chappie, John Michael Humphrey, Patrick Robert Verhoest, Eddie Yang
  • Azabenzimidazole Compounds
    Publication number: 20150322065
    Abstract: The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.
    Type: Application
    Filed: July 21, 2015
    Publication date: November 12, 2015
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward
  • Triazine derivatives
    Patent number: 9145427
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: September 29, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Byrce Tuttle, Patrick Robert Verhoest
  • Azabenzimidazole compounds
    Patent number: 9120788
    Abstract: The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 1, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward
  • Triazine Derivatives
    Publication number: 20150080401
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Triazine derivatives
    Patent number: 8933224
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: January 13, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Triazine Derivatives
    Publication number: 20140329820
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 6, 2014
    Applicant: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Pyrazolo[3,4-]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors
    Patent number: 8829010
    Abstract: The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: September 9, 2014
    Assignee: Pfizer Inc.
    Inventors: Christopher John Helal, Thomas Allen Chappie, John Michael Humphrey
  • Azabenzimidazole Compounds
    Publication number: 20140235612
    Abstract: The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward
  • PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS
    Publication number: 20140080806
    Abstract: The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.
    Type: Application
    Filed: May 24, 2012
    Publication date: March 20, 2014
    Inventors: Christopher John Helal, Thomas Allen Chappie, John Michael Humphrey
  • Imidazo[5,1-f][1,2,4]Triazines For The Treatment of Neurological Disorders
    Publication number: 20140066622
    Abstract: The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.
    Type: Application
    Filed: November 1, 2013
    Publication date: March 6, 2014
    Applicant: Pfizer Inc.
    Inventors: Christopher John Helal, Thomas Allen Chappie, John Michael Humphrey, Patrick Robert Verhoest, Eddie Yang
  • Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
    Patent number: 8598155
    Abstract: The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: December 3, 2013
    Assignee: Pfizer Inc.
    Inventors: Christopher John Helal, Thomas Allen Chappie, John Michael Humphrey, Patrick Robert Verhoest, Eddie Yang